Paper8324869
Disposition of total and unbound etoposide following high-dose therapy.
Schwinghammer TL and 6 others. Cancer Chemother Pharmacol, 1993. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Disposition of total and unbound etoposide following high-dose therapy. Papers, record 8324869. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8324869
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Marrow Transplantation | Major topic |
| Etoposide | Major topic |
| Adolescent | |
| Adult | |
| Female | |
| Half-Life | |
| Humans | |
| Male | |
| Middle Aged | |
| Protein Binding | |
| Regression Analysis | |
| Serum Albumin |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6644611 | Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis. | J Pharm Sci | 1983 | https://conductscience.org/library/papers/6644611 | PubMed |
| 2 | 1732431 | Increased teniposide clearance with concomitant anticonvulsant therapy. | J Clin Oncol | 1992 | https://conductscience.org/library/papers/1732431 | PubMed |
| 3 | 1640365 | Factors affecting in vitro protein binding of etoposide in humans. | J Pharm Sci | 1992 | https://conductscience.org/library/papers/1640365 | PubMed |
| 4 | 2026183 | Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease. | Exp Hematol | 1991 | https://conductscience.org/library/papers/2026183 | PubMed |
| 5 | 6574831 | Busulfan kinetics. | Clin Pharmacol Ther | 1983 | https://conductscience.org/library/papers/6574831 | PubMed |
| 6 | 6330904 | The role of autologous bone marrow transplantation in various malignancies. | Semin Hematol | 1984 | https://conductscience.org/library/papers/6330904 | PubMed |
| 7 | 2596777 | Busulphan and phenytoin. | Ann Intern Med | 1989 | https://conductscience.org/library/papers/2596777 | PubMed |
| 8 | 3643849 | Pharmacokinetics of high dose etoposide (VP 16-213). | Eur J Cancer Clin Oncol | 1986 | https://conductscience.org/library/papers/3643849 | PubMed |
| 9 | 2230875 | Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. | J Clin Oncol | 1990 | https://conductscience.org/library/papers/2230875 | PubMed |
| 10 | 6151067 | Convulsions due to high-dose busulphan. | Lancet | 1984 | https://conductscience.org/library/papers/6151067 | PubMed |
| 11 | 6690051 | Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. | Cancer Res | 1984 | https://conductscience.org/library/papers/6690051 | PubMed |
| 12 | 3598607 | Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. | J Clin Oncol | 1987 | https://conductscience.org/library/papers/3598607 | PubMed |
| 13 | 3548841 | Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. | Blood | 1987 | https://conductscience.org/library/papers/3548841 | PubMed |
| 14 | 2178849 | Pharmacokinetic drug interactions with phenytoin (Part I). | Clin Pharmacokinet | 1990 | https://conductscience.org/library/papers/2178849 | PubMed |
| 15 | 2910637 | Altered protein binding of etoposide in patients with cancer. | Clin Pharmacol Ther | 1989 | https://conductscience.org/library/papers/2910637 | PubMed |
| 16 | 1914374 | Relation of systemic exposure to unbound etoposide and hematologic toxicity. | Clin Pharmacol Ther | 1991 | https://conductscience.org/library/papers/1914374 | PubMed |
| 17 | 4063137 | The effect of etoposide on human CFU-GM. | Br J Cancer | 1985 | https://conductscience.org/library/papers/4063137 | PubMed |
| 18 | 3284691 | Pharmacokinetics of high-dose etoposide. | Clin Pharmacol Ther | 1988 | https://conductscience.org/library/papers/3284691 | PubMed |
| 19 | 6707876 | High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. | J Pharm Sci | 1984 | https://conductscience.org/library/papers/6707876 | PubMed |
| 20 | 3772420 | Etoposide pharmacokinetics in patients with normal and abnormal organ function. | J Clin Oncol | 1986 | https://conductscience.org/library/papers/3772420 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 27504190 | Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation. | J Pharm Health Care Sci | 2016 | https://conductscience.org/library/papers/27504190 | PubMed |
| 26040247 | Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia Relapse. | Arch Immunol Ther Exp (Warsz) | 2015 | https://conductscience.org/library/papers/26040247 | PubMed |
| 16524321 | Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. | Drug Saf | 2006 | https://conductscience.org/library/papers/16524321 | PubMed |
| 15139794 | Pharmacokinetic optimisation of treatment with oral etoposide. | Clin Pharmacokinet | 2004 | https://conductscience.org/library/papers/15139794 | PubMed |
| 8070032 | Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8070032 | PubMed |
| 7554043 | Etoposide protein binding in cancer patients. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7554043 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8324869
GET https://conductscience.org/api/papers/v1/8324869/references?page=2